l'm new to this particular forum but have been investing in biotechs for many years and see MSB as an outstanding prospect and am happy to sit while the trials take their course. The SP is typical of any biotech at this stage of development. Yes short selling has impacted the SP but the fact that phase 3 trial results are still a considerable time off means nobody should expect any serious rally.
Unfortunately todays investors appear to be looking for instant results so interest is minimal if trials are underway but some way from completion.
On the possibility of imminent partnering deals why would this company be entering into any deals now when their cash position is the envy of anyone in the drug discovery field and deals are always much more favourable when trial results are positive and completed.
Hang in there, be patient and perhaps look at the current SP as an opportunity to accumulate if your cash position allows.
Good luck to all holders
What a joke!, page-8
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |